Abstract
The annual ImmunoRad Conference has established itself as a recurrent occasion to explore the possibility of combining radiation therapy (RT) and immunotherapy (IT) for clinical cancer management. Bringing together a number of preclinical and clinical leaders in the fields of radiation oncology, immuno-oncology and IT, this annual event fosters indeed essential conversations and fruitful exchanges on how to address existing challenges to expand the therapeutic value of RT-IT combinations. The 8th edition of the ImmunoRad Conference, which has been held in October 2024 at the Weill Cornell Medical College of New York City, highlighted exciting preclinical and clinical advances at the interface between RT and IT, setting the stage for extra progress toward extended benefits for patients with an increasing variety of tumor types. Here, we critically summarize the lines of investigation that have been discussed at the occasion of the 8th Annual ImmunoRad Conference.
| Original language | English |
|---|---|
| Article number | 2507856 |
| Pages (from-to) | 2507856 |
| Journal | Oncoimmunology |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2025 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Animals
- Combined Modality Therapy
- Humans
- Immunotherapy/methods
- Neoplasms/therapy
- Radiotherapy/methods
Fingerprint
Dive into the research topics of 'Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference'. Together they form a unique fingerprint.Press/Media
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver